Effects of hypertonic saline on intracranial pressure variables in subarachnoid haemorrhage patients by Bentsen, Gunnar Kristoffer
  
 
 
Effects of hypertonic saline on  
intracranial pressure variables in 
subarachnoid haemorrhage patients 
 
 
 
Gunnar Kristoffer Bentsen 
 
 
 
Ph.D. thesis 
 
 
 
 
 
Division of Anaesthesiology and Intensive Care Medicine 
Rikshospitalet University Hospital 
University of Oslo 
Oslo, Norway 
2009 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
© Gunnar Kristoffer Bentsen, 2009
 
 
Series of dissertations submitted to the  
Faculty of Medicine, University of Oslo 
No. 714 
 
ISBN 978-82-8072-765-7 
 
 
All rights reserved. No part of this publication may be  
reproduced or transmitted, in any form or by any means, without permission.   
 
 
 
 
 
 
 
 
Cover: Inger Sandved Anfinsen. 
Printed in Norway: AiT e-dit AS, Oslo, 2009.   
 
Produced in co-operation with Unipub AS.  
The thesis is produced by Unipub AS merely in connection with the  
thesis defence. Kindly direct all inquiries regarding the thesis to the copyright  
holder or the unit which grants the doctorate.   
 
Unipub AS is owned by  
The University Foundation for Student Life (SiO) 
 3
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
”Following the intravenous injection of 30 per 
cent sodium chloride, the normal convexity of 
the brain in the trephine opening disappears 
soon after the injection is begun, so that the 
brain is seen to lie flat. As the intravenous 
injection of salt is continued, the brain falls 
away from the skull until the surface presented 
becomes concave. The maximum shrinkage has 
been observed usually in from fifteen to thirty 
minutes after the completion of the injection, 
when the brain lies flaccid, 3 to 4 mm below 
the inner table of the skull.” 
 
LH Weed and PS McKibben, 1919. 
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ABBREVIATIONS 
ABP Arterial blood pressure 
BBB Blood-brain-barrier 
CBF 
CBV 
Cerebral blood flow 
Cerebral blood volume 
CDO2 Cerebral oxygen delivery 
CI Cardiac index 
CNS Central nervous system 
CPM 
CPP 
Central pontine myelinolysis 
Cerebral perfusion pressure (CPP = MAP – ICP) 
CSF 
CVP 
DIND 
ELWI 
Cerebrospinal fluid 
Central venous pressure 
Delayed ischemic neurological deficit 
Extravascular lung water index 
EVD External ventricular drain 
FFT Fast Fourier transformation 
GCS Glasgow Coma Score 
GOS Glasgow Outcome Score 
HR Heart rate 
HS Hypertonic saline 
HSS 7.2% (72 mg/mL) saline in 6% (60 mg/mL) hydroxyethyl starch 
200/0.5 (sodium content: 1.23 mmol/mL)  
ICP Intracranial pressure 
ICU Intensive care unit 
ITBI Intrathorasic blood volume index 
IVH Intraventricular haemorrhage 
MAP Mean arterial pressure 
NS Normal saline 
SAH Subarachnoid haemorrhage 
SpO2 
TBI 
Peripheral oxygen saturation 
Traumatic brain injury 
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 INTRODUCTION 
 
Subarachnoid haemorrhage  
Definitions, incidence, and outcome 
Subarachnoid haemorrhage (SAH) is characterized by the presence of blood in the 
subarachnoid space; the space covering the central nervous system that normally only 
contains cerebrospinal fluid. The bleeding can be either traumatic or spontaneous. This thesis 
only deals with the spontaneous, non-traumatic bleedings, which in about 80 to 85% of the 
cases are due to the rupture of a cerebrovascular aneurysm (van Gijn and Rinkel, 2001).  
The overall incidence of spontaneous SAH is in meta-analyses reported to be 
somewhere around 10:100,000 annually, but with variations from six to eight in USA and 
most of Europe to around 20:100,000 in Finland and Japan (Linn et al., 1996; Teunissen et al., 
1996; Menghini et al., 1998; van Gijn and Rinkel, 2001). Women have a 1.6 times higher risk 
than men (Linn et al., 1996), and black people twice the risk of whites (Broderick et al., 1992) 
of experiencing a SAH. Smoking, hypertension, and alcohol abuse increase the risk for SAH 
(Teunissen et al., 1996). 
Case fatality rates are high in SAH compared with other forms of stroke, varying 
between 32% and 67%, with a weighted average of 51%, but the fatality rate has decreased 
over the last three to four decades by 0.5 to 1.0% annually (Hop et al., 1997; Johnston et al., 
1998; Koffijberg et al., 2008). Even though SAH accounts for only 3% of all strokes (Sudlow 
and Warlow, 1997), 4.4% of cerebrovascular deaths are due to SAH (Johnston et al., 1998). 
SAH also accounts for 27% of total years of potential life lost before age 65 due to 
cerebrovascular disease (Johnston et al., 1998). This is due to the high fatality rate and the fact 
that the population of SAH patients is younger than the populations with cerebral infarction 
and intracerebral haemorrhages. 
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About 50% of those who die, die within the first two days after the stroke (Stegmayr et 
al., 2004). This represents a challenge to the acute management of these patients. Of vital 
importance is prompt diagnosis, rapid transfer to a neurosurgical unit, early securing of the 
aneurysm, and optimal intensive care (Bakke and Lindegaard, 2007). 
Of the survivors, approximately one third need lifelong care (Hop et al., 1997), and 
almost a half of the survivors suffer life-long cognitive impairment (Hackett and Anderson, 
2000; Mayer et al., 2002). Hopefully, improved intensive care with avoidance of secondary 
insults can help reduce also these figures. 
 
Mechanisms of injury to the brain. 
Brain injury after SAH is a biphasic event.  
First there is the initial impact of the bleeding itself causing cerebral ischemia. A sharp 
increase in intracranial pressure (ICP) leads to a dramatic reduction in cerebral perfusion 
pressure (CPP) (Talacchi, 1993). But even after recovery of CPP, there is evidence of 
prolonged hypoperfusion with flow measured in different studies at 20 – 80% of baseline 
levels (Jackowski et al., 1990; Piepgras et al., 1995; Prunell et al., 2004). There is also 
evidence of loss of autoregulation, disruption of the blood-brain-barrier (BBB), cellular 
swelling leading to cerebral oedema, and initiation of apoptotic processes, but the 
understanding of the underlying mechanisms and the ultimate relevance of these early 
changes is still incomplete (Cahill et al., 2006; Mocco et al., 2007; Schubert and Thome, 
2008). 
Secondly, given that the patient has survived the impact of the bleeding, there is a 
more prolonged phase. Many patients experience bleeding into the ventricular system 
affecting drainage of cerebrospinal fluid (CSF). This may lead to the development of 
hydrocephalus and subsequent rise in ICP leading to ischemia within hours (Bakke and 
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Lindegaard, 2007). Cellular swelling and disruption of the BBB induces cerebral oedema, 
which also increases ICP. This process typically culminates after two to four days (Thiex and 
Tsirka, 2007), but may cause distortion and displacement of brain tissue resulting in 
compression of vital structures (“herniation” syndromes). Claassen et al. have reported the 
presence of cerebral oedema to be associated with poor outcome. Global oedema was found at 
admission in 8% of patients with an additional 12% developing delayed oedema (Claassen et 
al., 2002). Reaching peak incidence at about a week, delayed vasospasm may also cause 
seriously impaired cerebral blood flow (CBF) and ischemia. Radiographic evidence of 
vasospasm can be found in more than 50% of patients, but only half of these experience 
symptoms of delayed ischemic neurological deficits (DIND) (Keyrouz and Diringer, 2007). 
 Somewhere along the time line, there is also a periprocedural phase, where the source 
of bleeding is secured either by surgical clipping or endovascular coiling. These procedures 
also carry some risk. Complications may arise due to thrombosis, bleeding, induced 
vasospasm, or excessive traumatisation of brain tissue (Bakke and Lindegaard, 2007). 
 
Aspects of treatment 
In short, the goals of treatment are; meeting the neuronal metabolic needs at all times, 
avoiding secondary deterioration, and avoiding further bleeds. 
The avoidance of re-bleeding is achieved by surgical clipping or endovascular coiling 
of the aneurysm. The trend is to perform this intervention at an early stage. The risk of re-
bleeding is closely related to time and the occurrence of re-bleeding is strongly associated 
with poor outcome (Ohkuma et al., 2001; Bakke and Lindegaard, 2007). The risk of re-
bleeding is highest during the first 24 hours after the initial bleeding and immediate 
administration of tranexamic acid upon diagnosis of SAH may reduce the risk of early re-
bleeding (Hillman et al., 2002). 
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 Securing optimal oxygen and nutritional supply has many aspects. First, one important 
measure is to reduce the oxygen need. This can be achieved by avoiding hyperthermia and 
sedating the patient, in the final instance by inducing a pentobarbital coma. Sedation of the 
patient may warrant securing the airway and the institution of mechanical ventilation. 
Mechanical ventilation is often also needed because the patient is unconscious to begin with 
or because pneumonia impairs gas exchange to the degree that the patient is hypoxemic. By 
mechanical ventilation the oxygen supply and carbon dioxide removal can most often be well 
controlled. For the oxygen taken up in the lungs to be delivered to the brain we must ensure 
that the haemoglobin content is sufficient, and that the brain is perfused. This means that the 
CPP has to be adequate, and the blood pressure and cardiac output can be controlled by 
adequate volume supply and the use of vasoactive drugs when needed.  
As is obvious from the previous section, raised ICP is often a threat to adequate 
perfusion and cell function. Intracranial hypertension can be attenuated by sedation, head 
elevation, and temperature control. For short time relief of increased ICP, reduction of arterial 
CO2 content by hyperventilation can be very effective, but aggressive hyperventilation can 
induce grave vasoconstriction leading to ischemia in itself. Especially in patients suffering 
from acute hydrocephalus caused by intraventricular haemorrhage (IVH), external drainage of 
cerebrospinal fluid (CSF), either by a ventricular catheter or by the lumbar route is very 
helpful in rapidly decreasing the ICP. In extreme cases of cerebral swelling, the procedure of 
decompressive hemicraniectomy can be life saving (Schirmer et al., 2007; Hutchinson et al., 
2007). This brings me to the subject of osmotherapy, which is the last of the commonly 
applied strategies used to attenuate raised ICP.  
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Osmotherapy 
Context definition 
The use of osmotically active solutions to reduce the volume of the intracranial content 
(Paczynski, 1997). 
 
Mechanisms 
The water content of the brain approximates 80% (Bhardwaj, 2007). When we add that a 
small 1.6% reduction in water content yields a 90 mL reduction in brain volume (Cascino et 
al., 1983), we have the foundation for understanding osmotherapy.   
The osmotic pressure of a solution is proportional to the number of particles in a given 
volume (Rapoport, 1976), but osmotic effectiveness of solutions depends as much on the 
properties of the membrane(s) separating the different compartments of solutions as their 
respective molarities. This can be expressed as the membrane’s osmotic reflection coefficient 
() for a given solute. Given a reflection coefficient of zero, the membrane is completely 
permeable for that solute. On the other hand, if the membrane is impermeable, the value is 
one (Zornow, 1996).  
The properties of the BBB differ greatly from the properties of capillaries elsewhere in 
the body. Unlike “ordinary capillaries”, the BBB is virtually impermeable to small solute 
molecules like sodium and chloride. It is these compounds that regulate the water balance 
across the BBB. The importance of the colloid osmotic pressure, known from the Starling 
equation, is less in the uninjured brain; the flow of water is tightly controlled by the 
crystalloid osmotic pressure.  
 Another important property of the BBB, is the relative impermeability of molecules of 
water (Raichle et al., 1976). On 9 October 1991 the first water channel, Aquaporin-1, was 
discovered (Preston et al., 1992). Subsequently other aquaporins have been identified, and 
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Aquaporine-4 located in the brain may control most of the water transport across the BBB, 
and represent a rate limiting factor for this process. However, the importance of Aquaporine-4 
in human cerebral oedema is still undefined, but Aquaporine-4 has a potential for future 
therapeutic interventions (Agre et al., 2002; Chen et al., 2007; Bloch and Manley, 2007). 
The intravenous infusion of a hypertonic solution establishes an osmotic gradient 
between the intravascular space and the extracellular volume of the brain. This gradient 
provides a potent force to move water from the brain’s extra- and intracellular space into the 
capillaries. In this way, the volume of the brain is reduced and thereby the ICP (Zornow, 
1996). 
There are other theories as to how the osmotherapeutics reduce ICP. There are several 
variants of “haemodynamic” theories, all emphasizing the importance of dynamic changes in 
cerebral blood volume (CBV) (Paczynski, 1997). Muizelaar et al. have reported, from a study 
in cats, a rapid reduction in the diameter of arterioles and venules on the surface of the brain 
immediately after an intravenous mannitol bolus of 1 g/kg given during 1 minute (Muizelaar 
et al., 1983). Subsequently they reported how this effect on ICP was greater in patients with 
intact autoregulation, than in patients without (Muizelaar et al., 1984). I must, however, 
express methodological concerns regarding this last study as there seem to be repeated 
measurements in some patients and inclusion of patients with ICP above the stated inclusion 
criteria. The reduction in CBV was believed to be caused mainly by a vasoconstriction 
induced by reduction in blood viscosity improving blood flow (Muizelaar et al., 1983). This 
cerebral vasoconstriction has, however, been shown not to occur in other studies (Ravussin et 
al., 1985; Auer and Haselsberger, 1987). Auer et al. gave mannitol during 15 minutes, which 
is more in line with clinical practice than the one minute used by Muizelaar et al., and 
Ravussin et al. found reduced ICP despite increased CBV. 
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 It seems reasonable to speculate that instant, haemodynamic changes may account for 
some of the early (less than 15 minutes) effect seen on ICP after osmotherapy, whilst the 
osmotic effect is slower in onset, gradually dehydrating the brain towards a peek effect at 15 
to 30 minutes after administration of a hypertonic solution (Ziai et al., 2007). 
 
History 
The first description of osmotherapy applied to the central nervous system (CNS), is attributed 
to Weed and McKibben in 1919 (Weed and McKibben, 1919a; Weed and McKibben, 1919b). 
As research fellows in the Army Neurosurgical Laboratory at the Johns Hopkins Medical 
School, they were attempting to measure the transport of sodium salts from the blood into the 
CSF in cats. Upon intravenous injection of small volumes of 30% hypertonic saline (HS), they 
measured a marked and sustained decrease in ICP (Weed and McKibben, 1919b). This they 
found was due to shrinkage of the brain. They went on to describe how they through a 
craniotomy defect could observe the brain shrink away after HS injection with maximum 
effect 15 to 30 minutes after completion of the injection (Weed and McKibben, 1919a). 
 In 1927, intravenous delivery of osmotic agents for clinical practice was first 
formalized by Fremont-Smith and Forbes (Fremont-Smith and Forbes, 1927). They first used 
concentrated urea. 11 years later they were followed by Hughes et al. who demonstrated that 
concentrated solutions of human plasma proteins could reduce raised ICP (Hughes et al., 
1938). The use of plasma proteins was however limited because of fear of allergic reactions 
and high cost.  
 Wider attention was brought to the use of urea by Javid et al in the late 1950s (Javid 
and Settlage, 1956; Javid, 1961). With its low molecular weight of 60 Daltons, slow 
elimination from blood, and relatively slow BBB penetration ( = 0.48) (Qureshi and Suarez, 
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2000), it was a potent osmotic agent. It had however a significant potential for rebound 
cerebral oedema and side effects like phlebitis and haemolysis. 
 During early 1960s two other compounds replaced urea; mannitol and glycerol. 
Glycerol, introduced in 1964 is a trivalent alchohol (1,2,3-propanetriol), partially metabolized 
to CO2 and water (Cantore et al., 1964). With a reflection coefficient () of 0.59 (Qureshi and 
Suarez, 2000), it has a significant potential for causing rebound cerebral oedema. Side effects 
include haemolysis, haemoglobinuria, renal failure, and hyperosmolar coma (Bhardwaj, 
2007). Possibly due to tradition, glycerol has been used quite frequently throughout Asia and 
some centres in continental Europe, whereas mannitol has been the drug of choice in the UK 
and the Americas (Paczynski, 1997). Mannitol has also been the preferred choice in the 
Nordic countries. Only since late 80s has hypertonic saline, the compound that started it all, 
gained renewed interest. 
 
Mannitol 
As mentioned previously, mannitol has been the osmotic agent of choice in clinical practice in 
many countries for nearly five decades (Brain Trauma Foundation et al., 2007a). Mannitol has 
a molecular weight of 182 Daltons, and is an alcohol derivate of the sugar mannose. As 
opposed to urea, it has a short plasma half-life of 2 to 4 hours. The reflection coefficient () is 
0.9 (Qureshi and Suarez, 2000), which is much better than those of urea and glycerol. It does, 
however, leave the door open for rebound elevation of ICP upon repeated administrations. 
This has been much debated during the last two decades, and has reduced its use at least for 
repeated administrations (Garcia-Sola et al., 1991; Kaufmann and Cardoso, 1992; Kofke, 
1993; Polderman et al., 2003). In a study by Rudehill et al. the level of mannitol in the CSF 
increased after a single intravenous administration, and did not start to fall during the first 
eight hours after administration (Rudehill et al., 1993). Other side effects are acute renal 
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failure, particularly if serum osmolarity is > 320 mOsm/L combined with hypovolaemia 
(Worthley et al., 1988; Bullock, 1995). Mannitol is also of course foremost a diuretic, and will 
upon repeated administration lead to hypovolaemia if volume is not adequately substituted. 
 
Hypertonic saline 
After Velasco et al. in 1980 showed how bled dogs could be haemodynamically resuscitated 
with 4 mL/kg of 7.0% saline (Velasco et al., 1980), HS was evaluated for rapid resuscitation 
of patients with haemorrhagic shock during the 1980s and 90s. A small study by De Felippe Jr 
et al. (de Felippe Jr et al., 1980) was followed by a series of large randomised studies 
conducted in the pre-hospital setting (Holcroft et al., 1987; Vassar et al., 1991; Mattox et al., 
1991; Vassar et al., 1993a; Vassar et al., 1993b). In two of the studies by Vassar et al. (Vassar 
et al., 1991; Vassar et al., 1993a), improved survival was reported after HS as compared to 
isotonic resuscitation in patients suffering from traumatic brain injury (TBI); survival to 
discharge being 32 versus 16% in the first study and 34 versus 12% in the second. This 
boosted the wave of studies looking at HS and cerebral effects from the 1990s. 
The reflection coefficient () across the BBB for NaCl is 1.0 (Rapoport, 1976; 
Zornow, 1996; Qureshi and Suarez, 2000). In that respect, HS is an ideal osmotic agent. The 
main effect on elevated ICP is due to the “dehydrating” effect on the brain (Qureshi and 
Suarez, 2000; Ziai et al., 2007). The “dehydrating” effect of hypertonic saline (HS) has been 
shown both in animal studies (Todd et al., 1985; Zornow et al., 1989; Bacher et al., 1998; 
Toung et al., 2007; Chen et al., 2007) and in a MRI-study in humans (Saltarini et al., 2002). 
Theoretically most of the effect would be found in uninjured parts of the brain. This is 
supported by most studies (Zornow et al., 1989; Battistella and Wisner, 1991; Shackford et 
al., 1992). Normal brain tissue is “dehydrated” to accommodate the increase in intracranial 
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volume that results from oedema or haemorrhage. The effect in parts of the brain with injured 
BBB is more unpredictable (Chen et al., 2007). 
Cerebrovascular endothelial cells and red blood cells are also dehydrated, improving 
CBF and oxygen delivery due to increased vessel diameter and reduced size of the blood cells 
(Mazzoni et al., 1990; Shackford et al., 1992; Doyle et al., 2001). And like mannitol, HS 
lowers blood viscosity which may induce vasoconstriction with reduced CBV (Burke et al., 
1981; Muizelaar et al., 1983).  
Another advantage of HS is that it does not have the potentially detrimental diuretic 
effect like mannitol, which may lead to hypovolaemia and impaired cerebral perfusion (Arai 
et al., 1986; Worthley et al., 1988). 
There are a number of additional effects attributed to HS that deserve a brief 
mentioning even though most of the documentation is based on animal studies and has to date 
uncertain clinical implication. HS may have positive neurochemical effects, as HS solutions 
restore normal membrane resting potential by normalizing intracellular concentrations of 
sodium and chloride (Nakayama et al., 1985). HS may also have positive immunomodulatory 
effects on the inflammatory process generated by brain trauma, reducing leukocyte adherence 
and migration to injured parts of the brain (Hartl et al., 1997b). Several animal studies indicate 
a protective effect against bacterial infections (Coimbra et al., 1997; Shields et al., 2003; Chen 
et al., 2006), but very limited conclusions can be drawn as to the effect in humans (Kolsen-
Petersen, 2004). 
 The saline concentration in the solutions that have been investigated ranges from 1.4 to 
29.2%, and both solutions with and without the addition of a colloid have been used (Tables 
1-2, page 21)(Table 3, page 23). The addition of a colloid, typically 6% dextrane or 
hydroxyethyl starch, has in haemodynamic resuscitation studies prolonged the haemodynamic 
effect compared with HS alone (Smith et al., 1985; Kramer et al., 1986; Velasco et al., 1989). 
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For the attenuating effect on raised ICP, the addition of a colloid has not altered the effect 
compared with HS alone (Vassar et al., 1993a). Other studies have shown that intravenous 
infusion of 6% dextrane or hydroxyethyl starch solutions without HS do not reduce ICP 
(Gunnar et al., 1986; Ducey et al., 1989). This fits well with what can be expected from 
theoretical considerations based on the different properties of the BBB and capillaries 
elsewhere in the body. 
 
Animal studies 
Todd et al. were among the first to re-examine the cerebral effects of hypertonic saline 
solutions (Todd et al., 1985). They demonstrated in rabbits a decrease in brain water content, 
a decrease in ICP, and an increase in cerebral blood flow (CBF) following infusion of 
hypertonic Ringers’s solution (osmolality of 480 mOsm/kg). A number of animal studies 
followed. Studies looking at the effect of HS on ICP, CBF, or cerebral oxygen delivery 
(CDO2) are listed in Tables 1 and 2 (page 21). 
Although there are indications of possible problems with rebound increase in ICP in 
the material from Prough et al. from 1999 (Prough et al., 1999), the overall picture is that of 
reliable reduction in ICP and improvement in CBF. The later findings by German groups of a 
possible neuroprotective effect of HS is also encouraging (Heimann et al., 2003; Zausinger et 
al., 2004; Bermueller et al., 2006). These findings are supported by other studies not looking 
at effect on ICP (Hamaguchi and Ogata, 1995; Hamaguchi et al., 2002; Thomale et al., 2004). 
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Table 1. Animal studies investigating cerebral effects of HS without cerebral trauma. 
↓ ICP, ↑ CBF, ↑ CDO21,5% SL, RLSSPigSchmoker et al., 1991
↓ ICP, ↓ ICE6%S,6%HE,NS,WBSSPigDucey et al., 1989
↓ ICP after HS, ↓ CBF and CDO2
both groups
7.5% S, RLSSDogPrough et al., 1986
 ICP after HS, 
↑ICP after NS, D40
3%S, NS, 6%DSSDogGunnar et al., 1986
↓ ICP,  CBF and CDO27.5% S, RLSSDogPrough et al., 1985
↓ ICP, ↑CBF, cerebral dehydration1.6% S, NSNoneRabbitTodd et al., 1985
Results after HSStudy solutionsInjuryAnimal
 
↓, decreased; ↑, increased; , unchanged; SS, sirculatory shock induced by bleeding; HS, hypertonic saline; S, saline; NS, 
0.9% saline, RL, lactated Ringers; SL, sodium lactate; D, Dextrane 40; HE, hetastarch; WB, whole blood;  ICP, intracranial 
pressure; CBF, cerebral blood flow, CDO2, cerebral oxygen delivery; ICE, intracranial elastance 
 
Table 2. Animal studies investigating cerebral effects of HS with cerebral trauma. 
↓ICP, HSD also 
↓morphological damage
HSD, 7,2%S/HES, 
M, NS
SAHRatBermueller et al., 2006
↓ICP, HSD also 
↑ neurological recovery 
HSD, 7.5%S, NSSAHRatZausinger et al., 2004
CBF, ↓infarct size7.5%S/10%HES, 
10%HES, NS
VORatHeimann et al., 2003
↓ICP, rebound ↑ ICP7.2%S, 
7,2%S/20%HES, 
20%HES, 0.8%S
SS, SBDogPrough et al., 1999
↓ICP, BWC equal7.5%S, RLH, CryoSheepAnderson et al., 1997
↓ICP, ↑ ScO27.5%S, RLSS, CryoPigletTaylor et al., 1996
↓ CDO2 for both3%S, 10%HEH, PFICatDeWitt et al., 1996
↓ICP, ↑ CBF, ↑ CDO2, ↓contralat BWC
1.5%SL, RLCryoPigShackford et al., 1992
↓ ICP, ↑ CBF7.2% S, 0.8% SSS, SBDogPrough et al., 1991
↓ ICP, ↑ CBFHSD, RLSS, CryoPigWalsh et al., 1991
↓ ICP, ↓ contralat BWC7.5%S, RLHT, CryoSheepBattistella and Wisner, 
1991
Less ↑ ICP, ↓ contralat BWC1.4%RLHD, CryoRabbitZornow et al., 1989
↓ ICP, ↓BWC3%S, NS, 10%DSS, EBDogGunnar et al., 1988
Results after HSStudy solutionsInjuryAnimal
 
↓, decreased; ↑, increased; , unchanged; SS, circulatory shock induced by bleeding; H, moderate haemorrhage; HD, 
hemodilusion; HT, hypotension; EB, epidural balloon; SB subdural balloon; Cryo, cryogenic lesion; PFI, fluid-percussion 
injury; VO, occlusion of cortical veins; SAH, subarachnoid haemorrhage; HS, hypertonic saline; S, saline; NS, 0.9% saline, 
RL, lactated Ringer; SL, sodium lactate; D, Dextrane 40; HSD, 7.5%S in 6%D;HE, hetastarch; HES, hydroxyethyl starch; M, 
20% mannitol;  ICP, intracranial pressure; CBF, cerebral blood flow, CDO2, cerebral oxygen delivery; BWC, brain water 
content ; ScO2, cerebrovascular oxygen saturation 
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Human studies 
Several human studies have been performed looking at the effect of HS on ICP (Table 
3, page 23). Most of these were published prior to the publication of the studies included in 
this thesis, but also a handful during the time during completion of this thesis. I have included 
all of these in Table 3 (page 23) for completeness.  
The main finding in these reports is that of a reliable reduction in ICP after HS 
administration. In studies comparing HS to mannitol, HS is either equal or superior to 
mannitol. The magnitude of the maximum effect is described, but information about the time 
course of the effect is most often lacking. When is maximum effect reached? How long does 
the effect last, and is there rebound in patients with damaged BBB?  
Only two retrospective studies from Baltimore report negative effects. Increased in-
hospital mortality was found in one study (Qureshi et al., 1999) and loss of effect on ICP after 
3 – 4 days in another (Qureshi et al., 1998). Both these studies applied continuous infusion of 
3% sodium chloride / sodium acetate during several days. The indication for HS was cerebral 
oedema with or without intracranial hypertension. Mean ICP before initiation of HS was < 20 
mmHg in these studies and infusion was continued regardless of ICP. There was also a greater 
incidence of penetrating injury in the HS group in the study from 1999. My interpretation of 
these studies is that without signs of intracranial hypertension or decreased intracranial 
compliance, there is no clear indication for continuous infusion of HS. 
 Many of the studies are conducted with mixed patient populations, although there is a 
majority of TBI patients. All together there are only ten SAH patients included in the 
prospective studies. The effect of HS on ICP may very well differ between patient groups. 
Patients with localized BBB disruption will most probably respond much better to 
osmotherapy than those with generalized BBB disruption. 
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Table 3. Studies exploring the effect of hypertonic saline on ICP in humans. 
Reversal of TTH in 75% of cases,
ICP
30-60 mL 23.4% S
(bolus)
68
(76)
Retrospective, 
cohort
8stroke, 29ICH, 16 
SAH, 8 BT, 7other;
TTH
Koenig et al.,
2008
ICP, CPP, PI300 mL 3% S, 
(daily bolus, 20 
min. if ↑ ICP) 
18
(38)
Prospective, 
observational
TBI; 
ICP > 20mmHg
Huang et al., 
2006
↓ ICP, equal reduction, but longer 
duration
23,4% S vs M 
(bolus, S after M)
13RetrospectiveTBI; ↑ICP resistant 
to conv. therapy
Ware et al., 
2005
↓ICP, 
mean 57% vs 48% from baseline
HSH vs 15% M 
(1.4 vs 1.8mL/kg)
32Prospective, 
randomized
10TBI, 9SAH, 7CI, 
4ICH, 2other; 
ICP > 20mmHg
Harutjunyan et al., 
2005
↓ ICP, greater reduction and longer 
duration
100ml HSD vs. 
200ml 20% M
(bolus, 5 min.)
9Prospective, 
randomized,
cross-over
TBI; 
ICP > 20mmHg
Battison et al., 
2005
Less time with ↑ ICP, 
less clinical failure
7.5% S vs. 20% M 
2 ml/kg 
20Prospective, 
randomized
TBI; ↑ICP resistant 
to conv. Therapy
Vialet et al., 
2003
↓ ICP,  CVP. 
M: ↓CVP
3% S vs. M
(boluses, 3 days)
30Prospective, 
randomized
BT; surgeryDe Vivo et al., 
2001
↓ ICP, no adverse effects, 
3 dead due to ↑ ICP
3% S 
(cont. infusion)
68RetrospectiveTBI, childrenPeterson et al., 
2000
↓ ICP, no adverse effects, 
peak serum sodium 157-187 mEq/L
3% S 
(cont. infusion 
4 -18 days)
10Prospective, 
observational
TBI, children; ↑ICP 
resistant to conv. 
therapy
Khanna et al., 
2000
↓ ICP, mean ~30% from baseline, 
↑CPP, ↑ CO
1.5 mL/kg, 7,2%S 
(bolus, 15 min.)
14Prospective, 
observational
TBI; GCS < 13, ICP 
>15mmHg
Munar et al., 
2000
↑ in-hospital mortality3% S vs. NS
(infusjon)
36 
46c
Retrospective case-
control
TBIQureshi et al., 
1999
↓ICP, mean 42% from baseline, 
mean duration 3 hours
2 mL/kg 7.5% S 
(bolus)
10
(48)
Prospective, 
observational
6TBI, 4SAH; ↑ICP 
resistant to conv. 
therapy
Horn et al., 
1999
Improved haemodynamics, 
no adverse effects
3% S 
(cont. infusion)
29RetrospectiveSAH with vasospasm 
and hyponatremia
Suarez et al., 
1999
↓ ICP, ↓ventilator time, ↓RDS, 
↑survivale
1,7% S vs. RL
(cont. infusion)
32Prospective, 
randomized
TBI, childrenSimma et al., 
1998
↓ICP, mean 62% from baseline, 
mean duration several hours.
30 mL 23,4%S 
(bolus)
8
(20)
Retrospective5SAH, 3 other; ↑ICP 
resistant to conv. 
therapy
Suarez et al., 
1998
↓ICP, mean 43% from baseline, 
mean duration 101min.
100mL 10% S
(bolus, 5 min.)
6
(42)
Prospective, 
observational
5TBI, 1SAH; ↑ICP, 
↓CPP, no effect of 
M, THAM, Sorbitol
Schatzmann et al., 
1998
mean ΔICP: 
HSH: -11 mmHg, 
M: -6 mmHg
100mL HSH, vs. 
200mL, 20% M 
(bolus, 15 min.)
9
(30)
Prospective, 
randomized,
cross-over
Stroke; ↑ICP >25 
mmHg or pupil 
dilatation
Schwarz et al., 
1998
↓ ICP, ↓ oedema, 
rebound after 3-4 days
3%S
(cont. infusion)
27
(30)
Retrospective8TBI, 4BT, 1SAH, 
8ICH, 6CI
Qureshi et al., 
1998
Equally safe, 
HS group more severely ill
1.6%S vs. RL34Prospective, 
randomized
TBI – resuscitationShackford et al., 
1998
↓ ICP, ↑ CPP, 5 survivedHSH 
(bolus)
6 
(32)
Prospective, 
observational
TBI; ↑ICP resistant 
to conv. therapy
Hartl et al., 
1997a
Immediate ↓ ICP 7.5% S 
(bolus)
1Case reportTBI; ↑ICP resistant 
to conv. therapy
Einhaus et al., 
1996
↓ ICP 3% vs. 0.9%S 
(10mL/kg bolus)
18Prospective, rando-
mized, cross-over
TBI, childrenFisher et al., 
1992
Immediate ↓ ICP29.2% S 
(bolus)
2Case-seriesTBI; ↑ICP resistant 
to conv. therapy
Worthley et al., 
1988
Results after HSStudy solutionsNStudy designPatient population
 
↓, decreased; ↑, increased; , unchanged; N, number of patients (interventions); ICP, intracranial pressure; CPP, cerebral 
perfusion pressure; PI, cerebrovascular pulsatility index; BO, brain oedema; TBI, traumatic brain injury; SAH, subarachnoid 
haemorrhage; PO, postoperative; BT, brain tumour; ICH, non-traumatic intracerebral haemorrhage; CI, cerebral infarction; 
TTH, transtentorial herniation; GCS, Glasgow coma score; CO, cardiac output;  HS, hypertonic saline; S, saline; NS, 0.9% 
saline; HES, hydroxyethyl starch; RL, lactated Ringer; HSH, 7.2-7.5% HS in 6% HES; HSD, 7.5%S in 6%Dextran; M, 
mannitol; RDS, respiratory distress syndrome 
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Intracranial pressure monitoring  
 
Mean ICP 
Current state-of-art technology computes mean ICP during short time windows (e.g. 5 – 15 s 
duration). ICP can be measured by a number of different techniques, unfortunately all 
invasive. This means that measuring ICP must be weighed against the risks of infection and 
haemorrhage (Ghajar, 1995). The measurement of ICP via an intraventricular catheter, is 
internationally considered “the gold standard” (Guillaume and Janny, 1951; Lundberg, 1960; 
Czosnyka and Pickard, 2004; Steiner and Andrews, 2006). The advantages of this technique 
are the possibility of CSF drainage and the possibility to perform re-zeroing of the system, i.e. 
re-calibration towards atmospheric pressure. This technique requires, however, meticulous 
attention to adjustments of the zero level as the patient’s position is changed, and the 
monitoring is of course lost if the drain is clotted. The alternative technique is the use of a 
miniature, solid, intraparenchymal sensor. These allow continuous pressure monitoring at the 
same time as CSF can be drained through a ventricular catheter. The main disadvantage of 
most of the available systems is that they can not be re-calibrated once inserted, and that the 
zero pressure level may drift (Morgalla et al., 2001; Piper et al., 2001). Other techniques like 
subarachnoid or epidural probes, lumbar CSF pressure, tympanic membrane displacement, or 
transcranial Doppler, have not shown sufficient reliability for clinical use (Steiner and 
Andrews, 2006). 
 There are other problems with the measurement of mean ICP in addition to the 
technical aspects. We see in clinical practice how mean ICP changes abruptly when the 
patient’s position is changed. If an intraparenchymal probe is inserted on the right side, and 
the patients head is turned from resting on the left side to the right side, measured mean ICP 
might increase as much as 10 mmHg. Looking at trend plots of mean ICP, we regularly see 
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these different ICP levels directly relating to patient position. This can be explained by the 
simple fact that mean ICP is influenced by the weight of the brain above the point of 
measurement. Eide demonstrated in a small study how mean ICP measurements recorded 
simultaneously from two different intraparynchamal sensors differed considerably (Eide, 
2006b). A difference of above 5 mmHg was recorded 13% of the time and above 10 mmHg 
6% of the time. He describes how one sensor showed mean ICP > 20 mmHg while the other 
showed < 15 mmHg. Such a difference might have direct implications on patient treatment, no 
matter what the cause of the difference is.  
Another problem is deciding on what level of mean ICP should bring about an 
intervention to decrease ICP. What is a normal ICP? In young healthy volunteers lying down, 
average mean ICP was 11 mmHg (range 7 to 15 mmHg) (Albeck et al., 1991). In the upright 
position mean ICP was found to be in the range of -5 to +5 mmHg (Chapman et al., 1990). 
Starting measurements from the supine position, the decrease to this level was found to occur 
when elevating the head to about 45°, not changing much thereafter. In evaluating different 
mean ICP levels to outcome, one should therefore pay close attention to the degree of head 
elevation in order to be able to compare results.  
Although there is no definite agreement on the threshold for treatment, the guidelines 
from the Brain Trauma Foundation recommend treatment of mean ICP > 20 – 25 mmHg in 
traumatic brain injury (TBI) patients (Brain Trauma Foundation et al., 2007b). The decision in 
an individual patient is of course taken looking at ICP together with other variables like CPP, 
transcranial Doppler, clinical status, and radiological findings. It is not within the scope of this 
thesis to go into all these considerations, but at this point only to emphasise the need for 
further research that can improve the predictive power of our intracranial pressure 
measurements. 
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ICP waveform analysis  
One path that might prove worth while is looking at the intracranial pressure wave and 
intracranial compliance. Intracranial compliance relates to the changes in ICP subsequent to 
changes in intracranial volume at different pressure levels. When ICP is low and compliance 
is high, a small increase in volume only causes a small increase in pressure. If, however, the 
pressure is high and the compliance is low, this same increase in volume yields a far greater 
increase in pressure. It has been shown that this intracranial pressure-volume relationship is 
better described by a pulsatile than a static ICP (Avezaat et al., 1979; Gonzalez-Darder and 
Barcia-Salorio, 1989). 
A method for direct monitoring of brain compliance has been implemented in the 
Spiegelberg Brain Compliance monitor. This method relies on the evaluation of the pressure 
response to known small volume additions by inflating and deflating a balloon inserted within 
the cerebrospinal space. Initial trials indicate its usefulness, but implication for outcome 
remains to be demonstrated (Piper et al., 1999; Yau et al., 2002). 
A lot of work has been done by a group in Cambridge, UK, looking at waveform 
analysis of ICP (pulsatile ICP) (Czosnyka and Pickard, 2004). The ICP waveform consists of 
several components, but it is especially the amplitude of the component with a frequency 
equal to the heart rate that has gained most focus, the intracranial pulse pressure or ICP 
amplitude. The Cambridge group has described two ICP derived indexes (Czosnyka and 
Pickard, 2004). The first is called RAP (correlation coefficient (R) between AMP amplitude 
(A) and mean pressure (P); index of compensatory reserve). When RAP is close to +1, the 
amplitude varies directly with ICP, indicating a low intracranial compensatory reserve. The 
second index is a pressure-reactivity index called PRx. A positive index is correlated with 
poor autoregulation. Abnormal values have been demonstrated to predict poor outcome after 
head injury (Steiner et al., 2002).  
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The magnitude of “slow ICP waves” (frequency ½ - 3 per minute) has also been 
shown to correlate with outcome, a greater magnitude indicating favourable outcome 
(Lundberg, 1960; Balestreri et al., 2004). 
 My curiosity about waveform analysis and its possible use in clinical practice was 
awakened by the work performed at our institution by Eide and co-workers. He has developed 
at method of actually continuously measuring the heartbeat to heartbeat intracranial pulse 
pressure and displaying this in real time at the bed side (Eide, 2006a). Previously, information 
about single ICP waves has been derived from spectral analysis using fast Fourier 
transformation (FFT) (Christensen and Borgesen, 1989). FFT does, however, not include an 
algorithm for identification of the single ICP waves. The intracranial pulse pressure recorded 
using the new method is called “mean ICP wave amplitude”, and it was found to relate 
significantly to both the acute clinical state (Glasgow Coma Score, GCS) and the final clinical 
outcome (Glasgow Outcome Score, GOS) in SAH patients. This relationship could in that 
study not be demonstrated for mean ICP and mean CPP (Eide and Sorteberg, 2006). 
Moreover, a case report showed how a long-standing bad clinical state of a SAH patient was 
rapidly changed by turning management from being guided by static ICP (mean ICP) to being 
pulsatility (or waveform) guided according to the mean ICP wave amplitude (Eide et al., 
2007c). It was also reported how a reduction in intracranial pulsatility could be achieved by 
increased drainage of cerebro-spinal fluid (CSF) via an external ventricular drain (EVD) (Eide 
et al., 2007c). Given the positive indications that mean ICP wave amplitude could predict 
outcome, I found it important to investigate whether a medical intervention with HS could 
decrease mean ICP wave amplitude. An additional incentive for contributing research results 
regarding this new variable is all the technical and practical difficulties related to mean ICP 
that I have mentioned earlier.  
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AIMS OF THE THESIS 
 
1. Describe the effects of bolus infusion of 7.2% (72 mg/mL) saline in 6% (60 mg/mL) 
hydroxyethyl starch 200/0.5 solution (HSS) on the intracranial pressure (ICP) 
variables, mean ICP and mean ICP wave amplitude, and cerebral perfusion pressure 
(CPP) in patients with subarachnoid haemorrhage (SAH). 
2. Describe the time course of these effects, including time to maximum effect.  
3. Describe the magnitude of these effects. 
4. Describe the changes in serum sodium concentration, and how serum sodium is related 
to ICP during the study period. 
5. Describe haemodynamic effects. 
6. Describe how mean ICP and mean ICP wave amplitude are related. 
7. Compare the effect of HSS on mean ICP with the effect on mean ICP wave amplitude 
(intracranial pulse pressure). 
8. Compare the effect on intracranial pulse pressure with the effect on systemic arterial 
pulse pressure. 
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METHODS 
 
 
All data in the three studies have been collected from patients suffering from acute, non-
traumatic subarachnoid haemorrhage (SAH) admitted to the Intensive Care Unit at 
Rikshospitalet University Hospital. 
 All patients included were unconscious due to the nature of their disease and could not 
give their informed consent to participation. Possible risks and benefits were therefore given 
thorough evaluation. The protocols were approved by the Regional Ethics Committee for 
Medical Research and the Norwegian Medicines Agency. Close relatives were given oral and 
written information in accordance with the terms for approval by the Ethics Committee.  
   
Study design 
A common denominator of the studies was the effort taken to ensure as laboratory-like 
conditions as possible, given a clinical setting. The first measure to achieve this was of course 
to only include SAH patients, the second measure was to only include patients which were 
relatively stable before intervention, and the third was to make sure that nothing was done 
with the patient during the study period unless dictated by the rescue treatment protocol. 
In both Study I and II we looked at effects of HSS on mean ICP, CPP, and 
haemodynamics during a 210 minutes study period. In Study I relevant patients with mean 
ICP > 20 mmHg were included. This being an observational study, Study II was given a 
randomised, single-blinded, placebo-controlled design including patients with mean ICP < 20 
mmHg. Judged together, these two studies would then give sound evidence of an effect (Study 
II), magnitude of effect (Study I), and time course of the effect (Study I and II). Study III 
utilized data collected in a still ongoing prospective study looking at different ICP variables 
and their association to outcome. Instances where known doses of HSS were administered at 
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known times were selected from a large database of pressure recordings, and before and after 
values were analysed. 
 All data were recorded prospectively. In Study I and II they were analysed according 
to the predetermined plan drawn up in the protocols. In Study III, the data were prospectively 
collected as part of a different study still ongoing. The protocol for Study III was designed 
after data collection had started. 
 
Data collection 
Intracranial pressure was measured via a solid ICP sensor (Codman MicroSensor™, Codman, 
Raynham, MA) coupled to a Codman® pressure transducer (Codman ICP Express™, 
Codman, Raynham, MA). For the continuous arterial blood pressure (ABP) monitoring, an 
arterial cannula was placed in a radial or femoral artery and connected to a Baxter fluid sensor 
(Baxter, Deerfield, IL). Arterial blood pressure was zeroed at the level of the heart. Both 
signals together with heart rate (HR), central venous pressure (CVP), and peripheral oxygen 
saturation (SpO2) were coupled to a vital signs Siemens 9000XL Series Monitor (Siemens 
AG, Munich, Germany). Cardiac index (CI), intrathoracic blood volume index (ITBI), and 
extravascular lung water index (ELWI) were measured by use of the PiCCO system (Pulsion 
Medical Systems, Munich, Germany). Arterial blood gases, pH, haemoglobin, and sodium 
were analysed with the ABL 725 (Radiometer, Denmark). 
 In study I and II, values from the Siemens monitor and the PiCCO system were 
registered electronically on a bed side computer every 30 seconds (LabView, National 
Instruments, Austin, TX). False blood pressure values due to blood sampling were removed 
manually before analysis.  
In Study III a different setup for electronic data harvest was used. By means of the 
Siemens Infinity Gateway Software, the continuous ICP and ABP signals were transferred on 
 31 
line via the hospital network to a computer server and stored as raw data files with sampling 
rates of 100 Hz. These data were analysed retrospectively using an algorithm implemented in 
the software SM NeuroWave Version 2.0 (Eide, 2006a). Information on the time and amount 
of hypertonic saline administered was collected from the patient charts. 
 
Statistical methods  
All patients included in the studies were reported according to the principle of intention-to-
treat. Study I and II are very similar in design. Repeated measurements of continuous data 
were collected from different individuals. While Study I was an observational study of ten 
interventions in seven patients, Study II was a placebo-controlled comparison of two groups, 
total 22 patients. Mean values of measured variables for each patient from a 5 min period just 
prior to infusion of study drug served as baseline. For data acquired electronically every 30 
seconds, the mean value of all 5 minute periods throughout the 210 minute study period were 
calculated and used for analysis. 
In Study I comparisons of values at the time of maximum effect and at the end of the 
study were compared with baseline values applying Wilcoxon’s test for paired samples. Even 
though the changes were highly significant, we chose to display the graphs of mean ICP and 
CPP for the ten individual cases. Since the number of cases was so low, we found this to be 
the best way to convey the results truthfully to the reader.  
In Study II baseline values were also calculated as the mean of a 5-minute period prior 
to infusion of HSS, and mean values for each 5-minute interval throughout the study period 
were used for analysis like in Study I. Differences between the groups were assessed by un-
paired Student’s t-test with Welch correction when there were unequal variance. For analysis 
of demographic data, Mann-Whitney and chi-square tests were also used. The number of 
patients was equal to the number of cases. In this study we did not only compare maximum 
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effect to baseline levels, we calculated the area under the curve for the different variables and 
standardized by the length of the study to get the mean change for the whole period. This is a 
recommended approach to statistical analysis of serial measurements (Matthews et al., 1990).  
 In Study III we had a total of 52 registrations from 20 patients, ranging from one to six 
per patient. Due to possible bias because of repeated measurements, only the first registration 
in each patient was included in the main results. This is in accordance with the statistical 
recommendations that the sampling unit, or the “unit of analysis”, must be the patient in 
studies like this one (Altman and Bland, 1997). We did however include information also 
about calculations based on the total material of 52 registrations. A paired t-test was applied 
comparing values before and after intervention for each variable, correlation was calculated 
according to Pearson, and standard linear and multiple regression analyses were applied. P-
values <0.05/number of comparisons (Bonferroni correction) were considered significant. 
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SYNOPSIS OF RESULTS 
Paper I 
This study was designed to document the short term effects of 7.2% (72 mg/mL) saline in 6% 
(60 mg/mL) hydroxyethyl starch 200/0.5 solution (HyperHAES®) (HSS) on intracranial 
hypertension after subarachnoid haemorrhage (SAH). Primary outcome variables were 
changes in mean intracranial pressure (ICP), changes in cerebral perfusion pressure (CPP), 
and number of treatment failures, here defined as not reaching mean ICP < 20 mmHg and 
CPP > 60 mmHg during the study period. Secondary outcome variables were changes in 
cardiac index (CI), intrathoracic blood volume index (ITBI), and extravascular lung water 
index (ELWI). 
Ten interventions in seven patients were included. All patients suffered from 
spontaneous SAH, their source of bleeding had been secured, and they had raised mean ICP > 
20 mmHg. A bolus of 2 mL/kg of HSS was infused during 20 minutes, and registrations 
continued for a total of 210 minutes. A laboratory like setting was pursued.  
All interventions resulted in decreased mean ICP < 20 mmHg and elevation of CPP > 
60 mmHg, i.e. zero treatment failures. The mean value for maximum mean ICP decrease in 
percent of baseline was 58%, a mean decrease of 14.3 mmHg from a baseline of 25 mmHg. 
Maximum effect was reached at 40 minutes after start of infusion. The mean peak increase in 
CPP was 26%. In the eight cases recorded for 210 minutes, the mean ICP was still 35% below 
baseline values at the end of the study. The time course of changes in ICP and CPP is 
displayed in Figure 1B (page 38). We could also demonstrate an inverse relationship between 
mean ICP and serum sodium levels. The maximum mean serum sodium increase was 6.6 
mmol/L. There were no statistically significant changes to the secondary outcome variables 
(measured in only five cases), only a trend towards increase in CI (p = 0.06) and ITBI (p = 
0.06).  
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We concluded that the infusion of 2 mL/kg of HSS had a predictable and clinically 
significant beneficial effect on mean ICP and CPP. 
 
Paper II 
Study I being an observational study, this study was designed to strengthen those results. A 
group given 2 mL/kg of HSS was compared with a placebo group receiving 2 mL/kg of 
normal saline (NS). In order to do that, the inclusion criterion as to intracranial pressure was 
mean ICP between 10 and 20 mmHg. The design apart from this was very similar to Study I 
with almost the same outcome variables. Changes in mean ICP and CPP were however 
primarily analysed as the changes in mean values for the entire study period, not only 
maximum change and change at the end of the study period. 
 In the placebo-group, there were no changes in any variables indicating that the study 
design was valid. In the HSS group we found a significant reduction in mean ICP and increase 
in CPP. Mean difference between the groups (HSS – NS) in average ICP was -3.0 mmHg 
and CPP was 5.4 mmHg. Mean maximal change in mean ICP was -5.6 mmHg in the HSS 
group. No rebound increase in ICP was found during the study period. The temporal change 
was very similar to the one found in Study I (Figure 2, page 42). In addition, we demonstrated 
a significant increase in cardiac output in the HSS group. The changes in serum sodium found 
in the HSS group was quite similar to the findings in Study I, mean maximum increase of 5.6 
mmol/L measured at 30 minutes, and a level 3.3 mmol/L above baseline at the end of the 
study. 
 We concluded that HSS reduce mean ICP and increase CPP in SAH patients, and that 
positive haemodynamic effects can be found. Judged together with Study I we concluded that 
HSS attenuates increased mean ICP in SAH patients with a maximum effect reached at 20-30 
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minutes after the completition of the infusion. The magnitude of the effect would be expected 
to be in the range demonstrated in Study I.  
 
Paper III 
In this study we compared the effect of HSS on mean ICP with the effect on mean ICP wave 
amplitude in SAH patients. Mean ICP wave amplitude is the intracranial pulse pressure 
recorded according to the algorithm developed by Eide; each cardiac beat-induced single 
pressure wave is automatically identified, and the pressure variables are calculated for 
consecutive 6-second time windows (Eide, 2006a). We also compared the effect on mean ICP 
wave amplitude with the effect on systemic arterial pulse pressure. 
 The study included 52 interventions with different amounts of HSS in 20 SAH 
patients. Only the first intervention in each patient was included in the main results due to 
statistical reasons. It was found that both mean ICP and mean ICP wave amplitude were 
attenuated by HSS. A correlation was found between change in mean ICP and mean ICP wave 
amplitude, but no correlation was found between baseline values of mean ICP and mean ICP 
wave amplitude. There was also a difference as to whether the treatment goal was reached. 
The goals were defined as mean ICP < 15 mmHg and mean ICP wave amplitude < 5 mmHg. 
The goal was reached in 65% of cases for mean ICP, while only in 30% of cases for mean ICP 
wave amplitude. The study also documented that there was no correlation between systemic 
arterial pulse pressure and intracranial pulse pressure, indicating that the intracranial pulse 
pressure is no reflection of systemic pressure changes but represents the response to the 
intracranial volume changes with each heartbeat.  
 In conclusion, the study documents for the first time that a drug, in this case HSS, has 
an attenuating effect on pulsatile ICP. The low percentage of target achievement for mean ICP 
wave amplitude indicates, however, that the intracranial compliance state was less favourable 
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than expected in a majority of these SAH patients with mean ICP and mean CPP values 
within normal ranges. The results also showed that the value of mean ICP wave amplitude 
could not be deduced from the value of mean ICP or vice versa in any given individual 
patient. 
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DISCUSSION 
 
All three studies included in this thesis are about the effect of 7.2% (72 mg/mL) saline in 6% 
(60 mg/mL) hydroxyethyl starch 200/0.5 solution (HSS) on intracranial pressure (ICP) in 
patients suffering from acute, spontaneous, subarachnoid haemorrhage (SAH). There are, 
however, thematically two different trails that are relevant to separate. Study I and II on one 
hand, are documenting effects on the well known and much investigated variables mean ICP 
and cerebral perfusion pressure (CPP). Study III on the other hand, is more on the edge to less 
well described territory, contributing a piece of evidence concerning the newly described 
intracranial pressure variable; mean ICP wave amplitude. 
 To put the perspective right, the findings in this thesis can tell nothing about whether 
the use of HSS had any bearing on neurological outcome in the patients studied. But being 
based on clinical studies, the results can, judged together with available literature, have direct 
implications for our current practice treating these patients. I hope to supply the fundament for 
an educated answer to whether clinical practice can be modified based on the findings in this 
thesis. 
 Before continuing, I would like to make a small pause, and close a 85 years long loop 
between the initial findings in 1919 by Capt. Lewis H. Weed and 1st Lt. Paul S. McKibben at 
The Army Neuro-Surgical Laboratory, Johns Hopkins Medical School, their extensive 
research in cats, and our own findings in patients admitted to our intensive care unit at the 
beginning of the following century. The point is to visually illustrate the similarities between 
an ICP curve from one of their publications (Weed and McKibben, 1919b) (Figure 1A, page 
38) with our ICP curve from Study I (Figure 1B, page 38). 
During the time I have worked with this thesis, it has remained a mystery to me why 
hypertonic saline was not re-discovered before, as an osmotic agent in the context of 
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intracranial hypertension. HS is cheap and has a much higher blood brain barrier (BBB) 
reflection coefficient than the other drugs studied throughout the 20th century.  
A B
Figure 1. A: ICP curve from cat no. 1271 after IV infusion of 12 mL of 30% saline (Weed and 
McKibben, 1919b). B: Mean change in ICP and CPP after IV infusion of 2 mL/kg of 7.2% 
saline in 6% hydroxyethyl starch 200/0.5 solution in SAH patients, n = 10 (Paper I).  
ICP, intracranial pressure; CPP, cerebral perfusion pressure; IV, intravenous. 
Figure 1A used with the permission from The American Physiological Society. 
 
 
The relevance of ICP and CPP 
A fundamental assumption for the use of osmotherapy to reduce ICP is that raised ICP 
correlates with bad outcome. Even though there is no single study that beyond doubt proves 
that monitoring of ICP improves outcome as opposed to not monitoring ICP, there are strong 
indications that support its value.  
With data from 428 traumatic brain injury (TBI) patients, Marmarou et al. found that 
the proportion of hourly ICP readings greater than 20 mmHg was highly significant in 
explaining outcome (Marmarou et al., 1991). Several other authors have also demonstrated 
worsened outcome in patients with increased ICP (Marshall et al., 1979; Narayan et al., 1981; 
Fearnside et al., 1993). However, Resnick et al. failed to demonstrate such a correlation for 
ICP > 20 mmHg measured more than 96 hours after injury (Resnick et al., 1997). In 1999, 
Robertson et al. published a randomised study in 189 patients with severe head injury, 
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demonstrating that secondary ischaemic insults could be prevented with the implementation 
of a target management protocol based on ICP and CPP (Robertson et al., 1999). Patel and co-
workers have published an abstract showing a mortality rate twice as high among patients 
treated in non-neurosurgical units compared with patients treated in neurosurgical units (Patel 
et al., 2003). The availability of ICP monitoring is of course only one out of many factors 
differing between the groups in this study. All of these studies refer to TBI patients, and 
Treggiari et al. have summarised evidence in a recent review (Treggiari et al., 2007).  
Citerio et al. have published a survey looking at the treatment of 350 SAH patients in 
Italian neurosurgical centres, and found high intracranial pressure to be an independent factor 
related to unfavourable outcome (Citerio et al., 2007). Two groups have found outcome to be 
related to mean ICP and pulsatility in SAH patients (Eide and Sorteberg, 2006; Soehle et al., 
2007). Finally, Zanier et al. have documented the clinical advantages of monitoring ICP via a 
computerised system over manual recordings (Zanier et al., 2007). Based on all this I find it 
safe to conclude that monitoring of ICP and CPP is valuable to the patients suffering from 
severe head injury and severe SAH.  
 
Different ICP variables 
As pointed out earlier, the first two papers are concerned with mean ICP, and the last also 
with mean ICP wave amplitude. We have in the last paper referred to the two ICP variables 
respectively as static and pulsatile ICP. The pulsatile ICP reflects the difference between 
systolic and diastolic ICP, the static ICP (mean ICP) however, does not carry any information 
about the shape of the ICP curve. The static ICP is influenced by a number of factors besides 
pathological processes within the skull. Methodological factors such as the point of 
measurement and baseline pressure level determined by zero calibration and drift, greatly 
impacts the final measurement and has been discussed previously. 
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 Pulsatile ICP (mean ICP wave amplitude) or intracranial pulse pressure is however in 
many respects a more robust variable. It describes the dynamic pressure response evoked by 
each cardiac beat. It does not need a correct zero calibration and is not influenced by drift of 
the zero level (Eide, 2006b). Further, it is not influenced by alterations in head position like 
described for mean ICP. In the study by Eide, while mean ICP differed considerably between 
two sensors, the differences in single pressure wave amplitude were marginal (Eide, 2006b). 
A difference of > 1 mmHg was found in only 0.8% of the time windows registered. Also, the 
intracranial compliance is better described by the pulsatile than the static ICP (Avezaat et al., 
1979; Gonzalez-Darder and Barcia-Salorio, 1989; Eide et al., 2007a). With the availability of 
pulsatile ICP at the bed-side in real time, I find this variable worth investigating as a 
supplement to current standard neuromonitoring. 
 
Effects of HSS on mean ICP and CPP in SAH patients  
In Table 3 (page 23) I have listed the clinical studies looking at different concentrations of HS 
used with the intention of controlling raised ICP. There are few SAH patients included in 
these studies, and there are no studies with only SAH patients. There is also little information 
about the time course of the effect. Inspired by this lack of knowledge, the two first studies 
were designed to determine the short time effects on mean ICP and CPP of a HSS infusion in 
SAH patients only. The reason that there is two and not one study is that I wanted to carry out 
this research in a fashion as controlled as possible given a clinical setting, including a placebo 
control. A placebo control group could not be justified including patients with mean ICP > 20 
mmHg, which is the group of patients that is relevant to look at. Two quite similar studies 
were therefore designed, one observational where all patients had mean ICP > 20 mmHg, and 
one placebo-controlled where the patients had mean ICP 10 – 20 mmHg. An observational 
study can never prove that an intervention was the cause of changes documented. The changes 
 41 
could be due to natural courses or the effect of other interventions even if everything is kept 
unaltered. The thought was that if the findings were similar in the two studies, the placebo-
controlled study would strengthen the findings from the observational study. The magnitude 
of the effect of HSS would be reflected in the observational study where the inclusion criteria 
for osmotherapy were relevant. In both studies we paid much attention to keeping all other 
things that might affect ICP constant during the study period. No sudden increase in ICP 
should lead to inclusion and a five minute period prior to infusion of HSS supplied baseline 
values. During the 210 minute study period, the patients were not stimulated, their position 
were unchanged, likewise ventilation, infusion rates for vasopressors, sedatives, and fluids. 
The level of resistance towards CSF drainage was kept unaltered.  
The results in the group that received HSS in Study II did closely mimic those of 
Study I with a fall in mean ICP and rise in CPP, though with less absolute change as expected, 
as the patients included in Study II had far lower ICP at inclusion. There was no change in the 
placebo group (Figure 2, page 42). This indicated that the study design was valid, and that we 
managed to control other variables that might have affected ICP. We therefore concluded that 
HSS attenuates mean ICP and increases CPP in SAH patients.   
 
Temporal pattern of change 
The curves in Figure 2 (page 42) and Figure 1B (page 38) illustrates another important aspect; 
i.e. the temporal pattern of the effect. Maximum effect is not reached immediately, as it is 
when arterial CO2 partial pressure is reduced by hyperventilation. In our studies it took about 
twice the infusion time before the maximum effect was reached. In Weed and McKibben’s 
study it took 25-30 minutes after the end of the bolus (given during five minutes) (Figure 1A, 
page 38). I have found only two clinical studies that contain such information. The first is a 
report of two TBI patients given 250 and 100 mmol of NaCl during 10 minutes respectively 
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Figure 2. Changes in intracranial pressure (ICP) (top panel), and cerebral perfusion pressure 
(CPP) (bottom panel), after infusion of 2 mL/kg of study solution. HSS, 7.2% saline in 6% 
hydroxyethyl starch; NS, normal saline. 
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(Worthley et al., 1988). Maximum effect was reached about 20 minutes after the end of the 
infusions deduced from graphs included in the paper. The second report is in a study by 
Battison et al. including six TBI and three SAH patients, where HS was infused during 5 
minutes. The paper includes a time-series plot from one patient, where the time to maximum 
effect seems to be 20 – 30 minutes (Battison et al., 2005).  In our studies I and II, average time 
to maximum effect from start of infusion was 40 and 60 minutes respectively, the infusion 
times being 20 and 30 minutes.   
This is important information both for the practitioner and the scientist. For the 
scientist, this indicates that the major effect of HS in the brain is due to removal of water, not 
mainly due to haemodynamic effects that would be expected to display an immediate effect. It 
may also say something about the properties of Aquaporine-4, if it is correct that these 
channels represent a rate-limiting step for water flux across the blood-brain-barrier (BBB).  
For the practitioner using HS in clinical practice, it is very important to know when maximum 
effect of the intervention can be expected. 
 
Study solution 
Our choice of HS solution should be commented on. We chose a commercially available 
solution (HyperHAES®) containing 7.2% (72 mg/mL) saline in 6% (60 mg/mL) hydroxyethyl 
starch 200/0.5 (HSS). Converted to mmol, the sodium content is 1.23 mmol/mL. This solution 
was chosen for several reasons. The combination of 7.2 to 7.5% saline in either hydroxyethyl 
starch or dextrane has been extensively used in clinical research (Holcroft et al., 1987; Vassar 
et al., 1991; Mattox et al., 1991; Vassar et al., 1993a; Vassar et al., 1993b), and is as such 
known to be safe. We wanted our findings to be readily transferable to clinical practice, and 
using a solution that is available seemed sensible. 3% saline is quite frequently used in 
publications from the United States, but is seldom in stock in Norwegian hospitals. For the 
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reasons mentioned, and for issues related to the use of new drugs in medical research, we did 
not want to prepare our own solution for these studies. All our patients were sedated and had a 
central venous catheter in place, so the hypertonicity was not a problem. In acute, pre-hospital 
settings, the solution can also be given in a peripheral vein. Using a less concentrated solution 
would also have yielded a higher volume load which could become a problem in some 
patients with cardiac and/or renal impairments. 
 As mentioned previously under Introduction (page 19), the addition of 6% 
hydroxyethyl starch or dextrane to HS has been shown to prolong a positive haemodynamic 
effect, but not influence the effect on ICP. I therefore find it justified to attribute the 
intracranial pressure effects documented in our three studies to the HS component of the HSS 
solution.  
 
Dose and practical use 
The dose used in the first two studies was 2 mL/kg of 7.2% saline in 6% hydroxyethyl starch 
(HSS) (2.46 mmol Na+/kg). This is half of the conventional dose used in small-volume 
haemodynamic resuscitation research, but we had found 2 mL/kg to be sufficient in pilots 
prior to the studies. The idea was to not use a higher dose than necessary and thereby not 
increase serum sodium more than necessary, so that the treatment could be repeated if the 
clinical state indicates that. As discussed in Paper II, the findings from these studies indicate 
that a standard dose might be lowered from 2 mL/kg, as the maximum reduction in mean ICP 
in Paper I was > 50%. We now recommend a dose of 1 – 2 mL/kg. In practical use this has 
evolved into a standard dose of 100 mL of HSS during 10-15 minutes in the average 60 – 90 
kg adult. However, a proper dose-finding study should be made. 
 Are bolus doses the optimal way of administering HS as osmotherapy? There is no 
definite answer to that. Most of the clinical studies listed in Table 3 (page 23) report only 
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single or repeated boluses, but some have used continuous infusion. Simma et al. randomised 
children with TBI to an infusion of lactated Ringer’s solution (sodium 131 mmol/L) or HS 
(sodium 268 mmol/L) with the goal of a serum sodium of 145-150 mmol/L during three days 
in the HS group. An increase in serum sodium correlated with lower ICP and higher CPP. 
They also reported fewer interventions, fewer complications, and shorter ICU stay in the HS 
group (Simma et al., 1998). Qureshi et al. on the other hand reported increased in-hospital 
mortality in a group of TBI-patients receiving a 3% HS-infusion as compared to normal saline 
in a retrospective study (Qureshi et al., 1999). The infusion was targeted at a serum sodium 
level of 145 – 155 mmol/L. There was, however, more penetrating injury in the HS group and 
the infusion was continued even when mean ICP was normal. There are two studies on 
children with TBI from San Diego applying a different approach (Khanna et al., 2000; 
Peterson et al., 2000). In these studies, HS is infused on a sliding scale to achieve a target 
serum sodium level that would maintain mean ICP < 20 mmHg. The results in these studies 
were promising with good effect on ICP and CPP, and they also reported very high serum 
sodium levels without adverse effects, mean highest level in the study by Khanna et al. was 
170.7 mEq/L (range, 157 – 187 mEq/L).  
 I find the sliding scale approach logic, that the dose of HS should be dictated by the 
need, here defined by the level of mean ICP, instead of targeting a predefined level for serum 
sodium. It also underlines the need to pay attention to the serum sodium level at all times, not 
allowing it to drift. However, in clinical practice there is often a need for a bolus intervention 
in order to treat an increased ICP. Mere adjustments of a continuous infusion would not take 
effect rapidly enough. I would therefore recommend to give a bolus of HS as described 
previously when ICP > 20 mmHg and osmotherapy is indicated, followed by a continuous 
infusion to maintain the serum sodium level achieved after the bolus. When needed, a new 
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bolus can be administered, and the infusion continued to maintain the new sodium level. This 
can be pictured as a “stair-case approach” with respect to the serum sodium level. 
 
Adverse effects 
The classic adverse effect described in patients with rapidly increased serum sodium is central 
pontine myelinolysis (CPM). This has typically been described after rapid correction of pre-
existing chronic hyponatraemia (Sterns et al., 1986; Vassar et al., 1990; Qureshi and Suarez, 
2000; Verbalis, 2006). CPM has never been reported after elevation of a normal serum 
sodium level (Qureshi and Suarez, 2000; Himmelseher, 2007), but breakdown of the BBB 
followed by myelinolysis can occur if serum osmolality reaches 370 – 380 mOsm/kg (Soupart 
et al., 1996). Intracranial haemorrhages have been reported in small children and cats after 
abrupt changes in serum sodium (Finberg, 1967), but does not seem to be an issue in the 
context of adult neurointensive care. However, we have in our institution implemented safety 
precautions implying that one should avoid increasing serum sodium more than 15 
mmol/L/day. We found in Study I and II mean maximum increase in serum sodium well 
within this limit; 6.6 and 5.6 mmol/L after 2 mL/kg of HSS.  
Even though the reflection coefficient () across intact BBB for NaCl is 1.0, one has to 
be aware of possible rebound increase in ICP. Since one can imagine all degrees of damage to 
the BBB, NaCl might leek into brain tissue in injured areas, later contributing to rebound 
increase in ICP. One has also to be aware of the transport of organic osmolytes, e.g. 
myoinositol, glutamine, glutamate, taurine, and urea into the brain, gradually compensating 
for the acute hyperosmolar state created intravascularely after HS. (Lien et al., 1990; Sterns 
and Silver, 2006; Verbalis, 2006). This means, that after culmination of the intracerebral 
hypertension, one has to carefully and in a controlled manner reduce the serum sodium level 
back toward normal levels, allowing the brain to lose the accumulated organic osmolytes 
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again. Fortunately, the loss of osmolytes is more rapid than the uptake (Verbalis, 2006), but 
we recommend a reduction of serum sodium of no more than 10 mmol/L/day. I think that 
caution in tapering of the hypernatremic state can eliminate some problems that can be 
misconceived as rebound phenomena.  
We do also advise caution in patients with unsecured aneurysms. A substantial 
intracranial volume and pressure reduction might precipitate re-bleeding. I have however 
never seen figures relating re-bleeding to the application of osmotherapy, but the general risk 
of very early re-bleeding (first 24 hours) is as high as 15% when no antifibrinolytic drugs are 
given (Hillman et al., 2002). 
When using HS one has also always to be aware of the acute volume load that is 
introduced to the circulation, paying special attention to patients with pre-existing heart 
failure. We have, however, not encountered problems with this using 1 – 2 mL/kg of HSS. 
Neither have we been able to attribute special clinical problems to the inevitable 
hyperchloremic acidosis induced by the continuous and/or repeated administration of NaCl.  
 A significant risk of acute renal failure exists when mannitol is administered in large 
doses, especially when serum osmolarity is > 320 mmol/L (Bullock, 1995) and the patient is 
hypovolemic. This does not seem to be a problem to the same extent with HS, and a serum 
osmolality > 320 mmol/L is not considered a contraindication to its use (Qureshi and Suarez, 
2000). And as opposed to mannitol, repeated administration of HS would contribute to 
correction of a hypovolemic state, rather than contributing to it. 
 
Effects of HSS on mean ICP wave amplitude in SAH patients  
Bed-side measurement of single wave intracranial pulse pressure is available based on a 
method developed by Per Kristian Eide at our institution (Eide, 2006a). This is an interesting 
variable, given the methodological problems with mean ICP discussed previously, and the 
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emerging documentation that mean ICP wave amplitude (intracranial pulse pressure) is better 
correlated with outcome than mean ICP (Eide and Sorteberg, 2006; Eide, 2006c; Eide et al., 
2007b). 
 The measurement of intracranial pulse pressure is not a new thing. The fundamental 
difference in the new algorithm is that mean ICP wave amplitude is calculated based on exact 
measurements of single waves generated by each cardiac beat. Previous technologies have 
either only measured maximum and minimum ICP during a given time frame, e.g. 15 – 20 
seconds, the results thus “contaminated” by e.g. the effects of the respiratory cycle on the ICP 
curve, or calculated on the basis of Fast Fourier transformation.  
 One important finding in Study III is that there is no correlation between the amplitude 
of ICP and the amplitude of systemic arterial blood pressure (ABP). We can therefore 
conclude that mean ICP wave amplitude is an independent variable reflecting the response to 
intracranial volume changes induced by each cardiac beat, i.e. a reflection of the intracranial 
compliance. 
 The main finding of Study III was that mean ICP wave amplitude was attenuated by 
HSS. This has to my knowledge not been demonstrated before. However, the effect on mean 
ICP wave amplitude was not directly comparable to the effect on mean ICP. First, there was 
not a good agreement between the two measurements, signifying that the value of one of them 
can not be deduced from the other. Secondly, there was a great discrepancy in target 
achievement between the two variables. “Normal” mean ICP wave amplitude was only 
achieved in a minority of cases while “normal” mean ICP was achieved in a majority of cases. 
This suggests that the intracranial compliance state was less favourable than expected from 
mean ICP in a majority of these patients. This is in concordance with the clinical perception 
we have from our clinical day to day practice in the ICU, that a mean ICP of < 15 mmHg is 
not “good enough” for a number of our SAH patients. For example, the mean ICP may be 
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normal, but the patient does not wake up. Only upon further reduction in mean ICP e.g by 
increasing CSF drainage, does the patient wake up. This is illustrated by a case report by Eide 
et al. where a SAH patient with normal mean ICP still was not waking up after 44 days (Eide 
et al., 2007c). Only after changing to an ICP-wave guided management which brought about 
increased CSF drainage, did the patient wake up. The notion that increased mean ICP wave 
amplitude is indicative of an unfavourable state, is also supported by another case report by 
Eide et al. that showed how increased amplitude was associated with increased levels of brain 
metabolites indicative of ischemia (Eide et al., 2007a). All this challenges the thought that 
“normal” mean ICP has the same implications in the injured and non-injured brain. These are 
interesting aspects deserving further attention in the future. 
 A positive spin-off effect of measuring mean ICP wave amplitude with an online 
display of the actual ICP curve drawn on the basis of measurements at 100 Hz, is that one has 
a useful tool for judging whether the ICP measurement is valid. The diagnosis of a partly 
dislodged catheter can readily be made just by looking at the curve. And in addition the 
system will classify the measurements as invalid. This is information not supplied by mere 
mean ICP. 
 
Future clinical research questions 
Reporting short time effects of hypertonic saline (HS) on intracranial pressure (ICP) variables 
in subarachnoid haemorrhage (SAH) patients is important, but to link the use of HS or 
measurements of increased mean ICP wave amplitude to effects on outcome; that is the real 
challenge. 
 
• Further studies are needed to better enlighten many aspects related to the use of 
hypertonic saline in SAH patients with intracranial hypertension: 
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o Optimal dose 
o Bolus, continuous infusion, or a combination 
o Rebound phenomenon 
o Timing related to time since injury 
o Safety issues related to serum sodium levels and adverse effects 
• Interesting and valuable knowledge would presumably emerge from studies 
combining metabolic changes measured with micro dialysis, cerebral water content 
and cerebral blood flow derived from MRI-investigations, and intracranial pressure 
variables during administration of hypertonic saline. 
• There is an immediate need for more data relating mean ICP and mean ICP wave 
amplitude to neurological outcome. 
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MAIN CONCLUSIONS 
 
All conclusions relate to patients suffering from acute spontaneous subarachnoid haemorrhage 
(SAH) investigated in the intensive care setting. 
 
1. Intravenous bolus infusion of 7.2% (72 mg/mL) saline in 6% (60 mg/mL) 
hydroxyethyl starch 200/0.5 solution (HSS) during 20 – 30 minutes reduced 
intracranial pressure (ICP), both mean ICP and mean ICP wave amplitude, and 
increased cerebral perfusion pressure (CPP).  
2. Intravenous bolus infusion of normal saline (single blind placebo) had no effect on 
mean ICP or CPP, verifying stable study conditions. 
3. When HSS was infused as a bolus during 20 to 30 minutes, the reduction in mean ICP 
started almost immediately, but reached its maximum 20 to 30 minutes after the end of 
the infusion, thereafter tapering off, but without a rebound within 3 hours. 
4. When mean ICP was above 20 mmHg, 2 mL/kg of HSS (2.46 mmol Na+/kg) reduced 
mean ICP in average by more than 50% at time of maximum effect, and mean ICP 
remained below baseline three hours later. 
5. Changes in mean ICP were inversely related to changes in serum sodium levels, and 
mean maximum increase in serum sodium was about 6 mmol/L after 2 mL/kg of HSS . 
6. A bolus infusion of 2 mL/kg of HSS increased cardiac output in our patients. 
7. There was poor agreement between mean ICP and mean ICP wave amplitude, so the 
level of one variable cannot be deduced from the other for any given individual 
patient. 
8. When the target level for mean ICP was reached after HSS infusion, the target for 
mean ICP wave amplitude was reached only in a few patients. This suggests that the 
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intracranial compliance may be less favourable than expected in many SAH patients 
with normal mean ICP and CPP. 
9. There was no correlation between mean ICP wave amplitude (intracranial pulse 
pressure) and systemic arterial pulse pressure. This supports the view that mean ICP 
wave amplitude is reflecting the pressure response to intracranial volume changes 
induced by each cardiac beat, i.e. intracranial compliance. 
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IMPLICATIONS FOR CLINICAL PRACTICE 
 
The studies included in this thesis have documented that intravenous infusion of HSS has a 
reliable effect on increased mean ICP in SAH patients. Mean ICP is lowered and as a 
consequence of that, CPP is increased. Based on the findings of this thesis, which are 
supported by other published studies, I now find there is enough evidence to recommend the 
use of HS for osmotherapy in SAH patients, as an alternative to or a supplement to mannitol. 
 In clinical practice, the mode of administration could preferably be modified compared 
with the regime presented in this thesis. The findings from study I indicates that a bolus dose 
could be reduced from the 2 mL/kg of HSS used in the study, and in clinical practice, an 
infusion time of 20 to 30 minutes would be perceived as too long. Further, our studies show 
how the positive effects on the ICP variables are gradually reduced as serum sodium returns 
to pre-infusion levels. I would therefore recommend to give a bolus of HS, e.g. NaCl 1 – 2 
mmol/kg during 5 – 15 minutes, when ICP > 20 mmHg and osmotherapy is indicated, 
followed by a continuous infusion to maintain the serum sodium level achieved after the 
bolus. When needed, a new bolus can be administered, and the infusion continued to maintain 
the new sodium level. Since serum sodium in our studies increased by about 6 mmol/L after 
2.5 mmol/kg, there is room for repeated boluses per day without increasing serum sodium 
more than 15 mmol/L/day. The inverse relationship between serum sodium and mean ICP, 
also teaches us that a careful tapering of a hypernatremic state is important and necessary to 
avoid rebound increase in mean ICP. 
 In our patients, cardiac output increased after HSS. This is in most cases clearly 
beneficial, as many of these patients require vasopressors to achieve a satisfactory 
haemodynamic situation. HSS may therefore reduce the need for such drugs.  
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 It was not within the scope of this thesis to define the role of mean ICP wave 
amplitude in clinical practice. More research is needed, but the findings from Study III have 
taught us that the intracranial compliance situation is not necessarily good even though mean 
ICP and CPP is normal. So at least in the cases where the radiology findings are fine, mean 
ICP and CPP are fine, but the clinical state of the patient is not fine, these results lend support 
to actively try to improve intracranial compliance e.g by infusion of HS or by increasing CSF 
drainage. 
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